Soligenix to initiate Phase III trial of SGX942 to treat HNC-associated oral mucositis

Soligenix has obtained clearance from the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial of SGX942 (dusquetide) to treat oral mucositis caused in head and neck cancer (HNC) patients who are receiving chemoradiation (CRT) …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news